Fragile X syndrome is typically diagnosed between ages three and five, with current treatments limited to off-label medications and behavioral interventions for other conditions.
Alzheimer’s Disease is a chronic degenerative condition of the brain affecting more than 50 million people worldwide. It leads to gradual or rapid loss of cognitive ability i.e. the ability to perform tasks, think and remember clearly.
A gradual decline in cognitive function with aging is normal, but in a disease such as Alzheimer’s, the decline may begin earlier and progress faster. In the later stages of disease there are also effects on a person’s ability to function in normal daily life.
The condition is characterized by episodes of depressed mood that are frequently recurrent. Depressive disorder can also be chronic if episodes are prolonged without resolution, or persistent where depression continues for 2 or more years.
The company collaborates with the US FDA and other regulators to conduct clinical trials for its molecule, Xanamem, advancing it to late-stage development.
Actinogen Medical Limited’s corporate governance statement describes its governance framework and practices, referencing the Australian Securities Exchange Corporate Governance Council’s principles.
